Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Sep 08, 2024 1:06pm
33 Views
Post# 36213852

RE:Perplexity Ai's suggested pricing, margin, and marketing

RE:Perplexity Ai's suggested pricing, margin, and marketing At that monthly pricing if a product was used every month you can see how it could add up over a one year period. Could Dr. Li, for instance, etc. help drive 100,000 customers to annual consumption? 100,000 customers at $30 per month is $36 million annually less any discounts.  
If the risk period for cholesterol reduction and inflammation is moving beyond 10 years now neutraceuticals could be seen as an increasingly important medical intervention in a very large market.

prophetoffactz wrote:
Based on the information provided, here is a suggested pricing, margin, and marketing strategy for Cosciens Biopharma's programs:

Pricing Strategy

Oat Beta Glucan Chewable
  • Premium pricing to reflect the product's unique formulation and health benefits
  • Initial price point of $29.99-$39.99 for a 30-day supply
  • Subscription model offering 10-15% discount for recurring orders
Avenanthramides Nutraceutical
  • Mid-range pricing of $24.99-$34.99 for a 30-day supply
  • Tiered pricing based on dosage strength (low vs high dose options)
Yeast Beta Glucan Capsules
  • Competitive pricing of $19.99-$29.99 for a 30-day supply
  • Bulk purchase discounts to encourage larger orders

Margin Strategy

  • Target gross profit margins of 60-70% across all product lines
  • Focus on efficient manufacturing and economies of scale to improve margins over time
  • Explore direct-to-consumer sales channels to maximize profit potential

Marketing Strategy

Key Messages:
  • Science-backed formulations with proven health benefits
  • Unique extraction and purification technologies
  • Convenient delivery formats (chewables, capsules)
Channels:
  • E-commerce platforms as the primary sales channel
  • Social media marketing to build brand awareness
  • Partnerships with health/wellness influencers and bloggers
  • Content marketing highlighting clinical studies and product benefits
Tactics:
  • Free samples with first purchase to encourage trial
  • Loyalty program to incentivize repeat purchases
  • Educational content on cholesterol reduction, inflammation, and immune health
  • Targeted ads to health-conscious consumers and those with specific health concerns
Launch Plan:
  • Soft launch of Oat Beta Glucan chewable in H2 2024 leveraging Health Canada approval
  • Gradual rollout of additional products in 2025
  • Focus on building brand recognition and establishing market presence
By implementing this strategy, Cosciens Biopharma can position its nutraceutical products as premium, science-backed solutions while maximizing profitability and market penetration. The company should regularly review and adjust pricing and marketing tactics based on market response and competitive landscape.



<< Previous
Bullboard Posts
Next >>